Generation Bio Co
NASDAQ:GBIO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.12
4.35
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Generation Bio Co
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | US |
Market Cap | 93.5m USD |
Operating Margin |
-526%
|
Country | FR |
Market Cap | 6T USD |
Operating Margin |
-17 527%
|
Country | US |
Market Cap | 320.1B USD |
Operating Margin |
28%
|
Country | US |
Market Cap | 147.4B USD |
Operating Margin |
19%
|
Country | US |
Market Cap | 119.4B USD |
Operating Margin |
40%
|
Country | US |
Market Cap | 113.8B USD |
Operating Margin |
38%
|
Country | US |
Market Cap | 94.1B EUR |
Operating Margin |
-370%
|
Country | AU |
Market Cap | 135.4B AUD |
Operating Margin |
26%
|
Country | US |
Market Cap | 82.6B USD |
Operating Margin |
30%
|
Country | US |
Market Cap | 39.3B EUR |
Operating Margin |
-33%
|
Country | NL |
Market Cap | 34.3B EUR |
Operating Margin |
-22%
|
Generation Bio Co
Glance View
Generation Bio Co. is a genetic medicine company focused on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2020-06-12. The firm through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. The company is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. The company has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Generation Bio Co's most recent financial statements, the company has Operating Margin of -525.5%.